Related Experiment Video
Updated: Feb 11, 2026
Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
Published on: April 5, 2024
DTCM-glutarimide Delays Growth and Radiosensitizes Glioblastoma
Gabriela Molinari Roberto1, Helder Henrique Paiva2, Lucas Eduardo Botelho de Souza3
1Department of Biology, Faculty of Philosophy, Sciences and Letters at Ribeirao Preto, University of Sao Paulo, Brazil.
Background And Purpose:
Glioblastoma (GBM) is the most aggressive brain tumor. Even with the advent of temozolomide, patient survival remains poor, with expected median survival around 1 year from diagnosis. Consequently, the relentless search for new therapeutic strategies able to increase patient outcome persists. 3-[(dodecylthiocarbonyl) methyl] glutarimide (DTCM-g) is a new anti-inflammatory compound that already showed antitumor effects.
Materials And Methods:
Clonogenic survival, proliferation, apoptosis, cell cycle progression and invasion capacity of pediatric and adult GBM cell lines (U87MG, U251MG, SF188 and KNS-42) were evaluated under treatment with DTCM-g. The combined treatment with radiation was also evaluated in vitro and in vivo through xerographic models.
Results:
DTCM-g is able to impair proliferation, reduce clonogenic capacity and induce cell cycle arrest in GBM cell lines. No alteration in apoptosis rates was found after treatment. DTCM-g also reduces the invasion capacity of all GBM cell lines without alterations in MMP2 and uPa expression. Moreover, the drug radiosensitized GBM in vitro and in vivo.
Conclusion:
Although additional studies are still necessary to support our findings, our results suggest that DTCM-g may be a promising drug on the adjuvant treatment of GBM exhibiting antitumor effects, especially through radiosensitization.
Insights
The novel compound 3-[(dodecylthiocarbonyl) methyl] glutarimide (DTCM-g) effectively inhibits glioblastoma (GBM) growth and invasion. DTCM-g also enhances radiation therapy, showing promise as an adjuvant treatment for GBM.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor patient survival, even with current treatments like temozolomide.
- There is a critical need for novel therapeutic strategies to improve outcomes for GBM patients.
Purpose of the Study:
- To evaluate the antitumor effects of 3-[(dodecylthiocarbonyl) methyl] glutarimide (DTCM-g) on pediatric and adult glioblastoma cell lines.
- To assess the potential of DTCM-g as an adjuvant therapy, particularly in combination with radiation.
Main Methods:
- Assessed clonogenic survival, proliferation, apoptosis, cell cycle, and invasion of GBM cell lines (U87MG, U251MG, SF188, KNS-42) treated with DTCM-g.
- Evaluated the combined effects of DTCM-g and radiation in vitro and in vivo using xenograft models.
Main Results:
- DTCM-g impaired GBM cell proliferation, reduced clonogenic capacity, and induced cell cycle arrest.
- DTCM-g decreased GBM cell invasion without affecting MMP2 and uPa expression.
- The compound demonstrated radiosensitizing effects on GBM in vitro and in vivo.
Conclusions:
- DTCM-g exhibits significant antitumor effects against glioblastoma.
- DTCM-g shows promise as a radiosensitizing agent for adjuvant glioblastoma therapy.
Related Concept Videos
00:57Population Growth
02:36Meristems and Plant Growth
01:27Relationship Growth
01:29Exponential Growth
03:02Primary and Secondary Growth in Roots and Shoots
01:24Growth versus Fixed Mindset